Table 2.

Third-generation EGFR TKIs in clinical development in NSCLC

Agents	Binding mode	Selectivity	Status
Osimertinib (AZD9291)	Irreversible	EGFR TKI-sensitizing mutations and T790M	Approved, T790M +
Rociletinib (CO-1686)	Irreversible	EGFR TKI-sensitizing mutations and T790M	No longer in development
Olmutinib (BI1482694/HM61713)	Irreversible	EGFR TKI-sensitizing mutations and T790M	Approved (only South Korea), T790M +
ASP8273	Irreversible	EGFR TKI-sensitizing mutations and T790M	Phase II, Phase III
Nazartinib (EGF816)	Irreversible	EGFR TKI-sensitizing mutations and T790M	Phase I/II, Phase II
PF-06747775	Irreversible	EGFR TKI-sensitizing mutations and T790M	Phase I/II
Avitinib (AC0010)	Irreversible	EGFR TKI-sensitizing mutations and T790M	Phase I/II

Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor.